Shield Therapeutics PLC Jose A. Menoyo Appointed as Chief Medical Officer (9598M)
27 Septiembre 2021 - 12:59AM
UK Regulatory
TIDMSTX
RNS Number : 9598M
Shield Therapeutics PLC
27 September 2021
Shield Therapeutics plc
("Shield or the "Company" or the "Group")
Jose A. Menoyo MD Appointed as Chief Medical Officer
London, UK, 27 September 2021: Shield Therapeutics plc (LSE:
STX), a commercial stage pharmaceutical company with a focus on
addressing iron deficiency with its lead product Accrufer(R)/
Feraccru(R) (ferric maltol), announces that Jose A. Menoyo, M.D.,
is joining Shield's Senior Executive Team as Vice President and
Chief Medical Officer with immediate effect.
Jose A. Menoyo, M.D.
Prior to joining Shield, Dr. Menoyo served as Head of US Medical
Affairs at Alexion Pharmaceuticals, Inc. ("Alexion"), a publicly
traded biotechnology company, acquired by AstraZeneca in July 2021.
In this role, Dr. Menoyo led the Medical Affairs and Health
Outcomes and Research teams that supported several launches in the
rare disease area. Prior to his role at Alexion, Dr. Menoyo was the
Sr. Vice-President of Clinical Development and Medical Affairs for
ZS Pharma, which was eventually acquired by AstraZeneca. Previous
biopharmaceutical experience includes leadership roles at Amgen,
Genzyme, and Sanofi.
Dr. Menoyo completed his Internal Medicine and Nephrology
Fellowship at Hahnemann University Hospital and Medical College of
Pennsylvania and will be reporting to Greg Madison, CEO.
Greg Madison, CEO of Shield, said: "Dr. Menoyo brings more than
25 years of experience in medical affairs, drug development, and
regulatory leadership across both large and small publicly traded
biopharmaceutical companies which includes successful drug global
launches and commercialisation support. Dr. Menoyo has extensive US
and Global experience in building and leading high performing teams
and his particular and proven expertise in establishing and
executing Medical Affairs strategies will be extremely valuable to
Shield for the launch of Accrufer in the US.
The Company also confirms that further to the announcement
issued on 28 May 2021, Tim Watts will resign from the Board with
effect from 30 September 2021 and no longer have any role with the
Group from that date.
"I would like to thank Tim for his crucial role in bringing
Shield to the point at which Accrufer can be launched in the US and
wish him well for the future. "
For further information, please contact:
Shield Therapeutics plc +44 (0) 191 511 8500
Greg Madison (CEO)
Hans-Peter Rudolf, CFO
Peel Hunt LLP - Nominated Adviser & Joint
Broker +44 (0) 20 7148 8900
James Steel / Christopher Golden
finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Alice Lane/ George Dollemore
Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne/ Alice or shield@walbrookpr.com
Woodings
About Shield
Shield is a commercial stage, pharmaceutical company with a
focus on addressing iron deficiency with its lead product Feraccru
(R) /Accrufer (R) (ferric maltol), a novel, stable, non-salt based
oral therapy for adults with iron deficiency with or without
anaemia.
Shield's lead product, Feraccru(R)/Accrufer(R), has been
approved for use in the United States, European Union, UK,
Switzerland and Australia and has exclusive IP rights until the
mid-2030s. The Group is currently launching Accrufer(R) in the US.
Feraccru(R) is already being commercialised in the UK and European
Union by Norgine B.V., who also have the marketing rights in
Australia and New Zealand. Shield also has an exclusive licence
agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialisation of Feraccru(R)/Accrufer(R) in
China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUUWBUPGGAC
(END) Dow Jones Newswires
September 27, 2021 01:59 ET (05:59 GMT)
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De May 2023 a May 2024